Remove 2029 Remove Diabetes Remove Documentation
article thumbnail

California’s low-cost insulin plans receive $100m manufacturing boost

Pharmaceutical Technology

The documents state that a partnership with a CMO would be cheaper than the state directly manufacturing insulin. The bill still must pass the Senate, and moreover, how uninsured people with diabetes will deal with steep prices still remains a question. In-house manufacturing the norm. Industry split over the pricing issues.